Michael Ihnat to Cell Line, Tumor
This is a "connection" page, showing publications Michael Ihnat has written about Cell Line, Tumor.
Connection Strength
1.175
-
A novel multidrug resistance phenotype of bladder tumor cells grown on Matrigel or SIS gel. Cancer Lett. 2005 Jan 20; 217(2):171-80.
Score: 0.176
-
Identification of novel drugs to target dormant micrometastases. BMC Cancer. 2015 May 14; 15:404.
Score: 0.090
-
A small molecule with anticancer and antimetastatic activities induces rapid mitochondrial-associated necrosis in breast cancer. J Pharmacol Exp Ther. 2015 May; 353(2):392-404.
Score: 0.088
-
Development and characterization of a preclinical model of breast cancer lung micrometastatic to macrometastatic progression. PLoS One. 2014; 9(5):e98624.
Score: 0.084
-
Suppression and activation of the malignant phenotype by extracellular matrix in xenograft models of bladder cancer: a model for tumor cell "dormancy". PLoS One. 2013; 8(5):e64181.
Score: 0.078
-
Synthesis and biological activity of 5-chloro-N4-substituted phenyl-9H-pyrimido[4,5-b]indole-2,4-diamines as vascular endothelial growth factor receptor-2 inhibitors and antiangiogenic agents. Bioorg Med Chem. 2013 Apr 01; 21(7):1857-64.
Score: 0.077
-
N4-(3-Bromophenyl)-7-(substituted benzyl) pyrrolo[2,3-d]pyrimidines as potent multiple receptor tyrosine kinase inhibitors: design, synthesis, and in vivo evaluation. Bioorg Med Chem. 2012 Apr 01; 20(7):2444-54.
Score: 0.072
-
Mutant p53 facilitates pro-angiogenic, hyperproliferative phenotype in response to chronic relative hypoxia. Cancer Lett. 2007 May 08; 249(2):209-19.
Score: 0.049
-
Role of HIF signaling on tumorigenesis in response to chronic low-dose arsenic administration. Toxicol Sci. 2005 Aug; 86(2):248-57.
Score: 0.045
-
Novel pyrazolo[4,3-d]pyrimidine microtubule targeting agents (MTAs): Synthesis, structure-activity relationship, in vitro and in vivo evaluation as antitumor agents. Bioorg Med Chem Lett. 2021 06 01; 41:127923.
Score: 0.034
-
Potential of substituted quinazolines to interact with multiple targets in the treatment of cancer. Bioorg Med Chem. 2021 04 01; 35:116061.
Score: 0.033
-
Design, synthesis and preclinical evaluation of 5-methyl-N4-aryl-furo[2,3-d]pyrimidines as single agents with combination chemotherapy potential. Bioorg Med Chem Lett. 2018 10 01; 28(18):3085-3093.
Score: 0.028
-
Synthesis and evaluation of 5-(arylthio)-9H-pyrimido[4,5-b]indole-2,4-diamines as receptor tyrosine kinase and thymidylate synthase inhibitors and as antitumor agents. Bioorg Med Chem Lett. 2017 04 01; 27(7):1602-1607.
Score: 0.025
-
A new anti-glioma therapy, AG119: pre-clinical assessment in a mouse GL261 glioma model. BMC Cancer. 2015 Jul 17; 15:522.
Score: 0.023
-
The design, synthesis and biological evaluation of conformationally restricted 4-substituted-2,6-dimethylfuro[2,3-d]pyrimidines as multi-targeted receptor tyrosine kinase and microtubule inhibitors as potential antitumor agents. Bioorg Med Chem. 2015 May 15; 23(10):2408-23.
Score: 0.022
-
The design and discovery of water soluble 4-substituted-2,6-dimethylfuro[2,3-d]pyrimidines as multitargeted receptor tyrosine kinase inhibitors and microtubule targeting antitumor agents. Bioorg Med Chem. 2014 Jul 15; 22(14):3753-72.
Score: 0.021
-
Evaluation of 99mTc-probestin for imaging APN expressing tumors by SPECT. Bioorg Med Chem Lett. 2013 Sep 15; 23(18):5049-52.
Score: 0.020
-
Solid phase synthesis and biological evaluation of probestin as an angiogenesis inhibitor. Bioorg Med Chem Lett. 2013 Jun 15; 23(12):3561-4.
Score: 0.019
-
N2-Trimethylacetyl substituted and unsubstituted-N4-phenylsubstituted-6-(2-pyridin-2-ylethyl)-7H-pyrrolo[2,3-d]pyrimidine-2,4-diamines: design, cellular receptor tyrosine kinase inhibitory activities and in vivo evaluation as antiangiogenic, antimetastatic and antitumor agents. Bioorg Med Chem. 2013 Mar 01; 21(5):1312-23.
Score: 0.019
-
Novel tricyclic indeno[2,1-d]pyrimidines with dual antiangiogenic and cytotoxic activities as potent antitumor agents. Bioorg Med Chem. 2012 Jul 15; 20(14):4217-25.
Score: 0.018
-
Synthesis and evaluation of novel Tc-99m labeled probestin conjugates for imaging APN/CD13 expression in vivo. Bioconjug Chem. 2012 Jan 18; 23(1):115-24.
Score: 0.018
-
N4-Aryl-6-substitutedphenylmethyl-7H-pyrrolo[2,3-d]pyrimidine-2,4-diamines as receptor tyrosine kinase inhibitors. Bioorg Med Chem. 2012 Jan 15; 20(2):910-4.
Score: 0.018
-
Design, synthesis and evaluation of 2-amino-4-m-bromoanilino-6-arylmethyl-7H-pyrrolo[2,3-d]pyrimidines as tyrosine kinase inhibitors and antiangiogenic agents. Bioorg Med Chem. 2010 Jul 15; 18(14):5261-73.
Score: 0.016
-
Synthesis and biological activity of N(4)-phenylsubstituted-6-(2,4-dichloro phenylmethyl)-7H-pyrrolo[2,3-d]pyrimidine-2,4-diamines as vascular endothelial growth factor receptor-2 inhibitors and antiangiogenic and antitumor agents. Bioorg Med Chem. 2010 May 15; 18(10):3575-87.
Score: 0.016
-
The contribution of a 2-amino group on receptor tyrosine kinase inhibition and antiangiogenic activity in 4-anilinosubstituted pyrrolo[2,3-d]pyrimidines. Bioorg Med Chem Lett. 2010 May 15; 20(10):3177-81.
Score: 0.016
-
Novel STAT3 phosphorylation inhibitors exhibit potent growth-suppressive activity in pancreatic and breast cancer cells. Cancer Res. 2010 Mar 15; 70(6):2445-54.
Score: 0.016
-
Single agents with designed combination chemotherapy potential: synthesis and evaluation of substituted pyrimido[4,5-b]indoles as receptor tyrosine kinase and thymidylate synthase inhibitors and as antitumor agents. J Med Chem. 2010 Feb 25; 53(4):1563-78.
Score: 0.016
-
Docosahexaenoic acid inhibits superoxide dismutase 1 gene transcription in human cancer cells: the involvement of peroxisome proliferator-activated receptor alpha and hypoxia-inducible factor-2alpha signaling. Mol Pharmacol. 2009 Sep; 76(3):588-95.
Score: 0.015
-
Design, synthesis and biological evaluation of substituted pyrrolo[2,3-d]pyrimidines as multiple receptor tyrosine kinase inhibitors and antiangiogenic agents. Bioorg Med Chem. 2008 May 15; 16(10):5514-28.
Score: 0.014
-
Novel 5-substituted, 2,4-diaminofuro[2,3-d]pyrimidines as multireceptor tyrosine kinase and dihydrofolate reductase inhibitors with antiangiogenic and antitumor activity. Bioorg Med Chem. 2005 Sep 15; 13(18):5475-91.
Score: 0.011